SKAN.SW stock trades at CHF 43.85 on the SIX as markets closed on 23 Mar 2026, ahead of earnings due 24 Mar 2026. Investors will focus on margins and post-pandemic service growth. The firm shows EPS CHF 0.72 and PE 60.90, highlighting high valuation relative to peers. Volume was 42,384 shares, slightly above average.
Earnings timing and immediate catalysts for SKAN.SW stock
SKAN Group AG reports after hours on 24 Mar 2026. Investors expect commentary on order intake and services revenue. The Equipment and Solutions and Services segments will drive guidance. Watch margin reconciliation and backlog disclosure for immediate price reaction.
Financial snapshot and valuation: SKAN.SW stock analysis
SKAN.SW stock is trading at CHF 43.85 with market cap CHF 985,902,527 and shares outstanding 22,483,524. Trailing metrics show PE 60.90, EPS 0.72, and PB 5.57. Free cash flow yield is 0.02, and current ratio is 1.15. These figures suggest tight valuation versus cash generation.
Sector comparison and risks for SKAN.SW stock outlook
In Healthcare, average PE is 29.67 and average net margin is 19.6%. SKAN.SW stock has a higher PE and lower net margin at 4.87%, raising relative valuation risk. Debt is low at debt/equity 0.06, which helps balance the valuation concern. Key risks are margin pressure and inventory days at 447.76.
Technical read and trading signals for SKAN.SW stock
Price sits near the Bollinger lower band at CHF 43.60, and RSI reads 25.39, indicating oversold conditions. Average volume rose to 42,384 versus avg 32,589. Momentum indicators point to selling pressure but possible short-term relief if earnings beat.
Meyka grade and forecast: SKAN.SW stock price targets
Meyka AI rates SKAN.SW with a score of 72.71 out of 100 (Grade B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly CHF 37.64, quarterly CHF 43.33, and yearly CHF 45.66. Compared to the current price CHF 43.85, the yearly forecast implies upside 4.13%, and the monthly target implies downside 14.16%. Forecasts are model-based projections and not guarantees.
Investment implications and practical strategy for SKAN.SW stock
For traders, a beat could lift price toward CHF 50.00 in a momentum scenario. For investors, high PE and low free cash flow yield support a cautious stance. Consider position sizing and stop-loss levels. There is no broad analyst price target consensus available publicly.
Final Thoughts
SKAN.SW stock enters the earnings window priced at CHF 43.85 with high valuation metrics and mixed fundamentals. Key positives include low leverage and strong gross margins. Key negatives are a high PE 60.90, long inventory days, and a low free cash flow yield. Meyka AI’s model projects a yearly target CHF 45.66, implying ~4.13% upside from today’s close. Shorter-term monthly forecasts point to a CHF 37.64 downside scenario. Traders should watch order intake, services growth, and margin commentary on 24 Mar 2026. Investors should weigh the B+ Meyka grade against valuation risk and sector peers. For further real-time updates use Meyka AI-powered market analysis and the company site for filings source and corporate updates on LinkedIn source.
FAQs
When does SKAN Group AG release earnings?
SKAN Group AG reports earnings on 24 Mar 2026 after market hours. Expect commentary on order intake, services revenue, and margin guidance which are key for SKAN.SW stock moves.
What valuation metrics matter for SKAN.SW stock?
Watch PE 60.90, EPS CHF 0.72, and PB 5.57. Also monitor free cash flow yield and inventory days, as these drive valuation and short-term liquidity concerns for SKAN.SW stock.
What is Meyka AI’s view for SKAN.SW stock?
Meyka AI rates SKAN.SW 72.71/100 (B+, BUY) and forecasts yearly CHF 45.66. This implies modest upside from CHF 43.85. Forecasts are model outputs and not guarantees.
How does SKAN.SW stock compare to healthcare peers?
SKAN.SW stock has a higher PE than the healthcare average PE 29.67, lower net margin, and much lower debt. That mix raises valuation risk versus peers in the sector.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)